Fluorescence in situ hybridizationa highly efficient technique of molecular diagnosis and predication for disease course in patients with myeloid leukemias

Cancer Genetics and Cytogenetics

Volumn 131, Issue 2, 2001, Pages 125-134

  Amare, P S ^a   Baisane, C ^a   Saikia, T ^a   Nair, R ^a   Gawade, H ^a   Advani, S ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CHROMOSOME REARRANGEMENT; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; KARYOTYPING; MALE; METAPHASE; PREDICTION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RECURRENT DISEASE; RELAPSE; ADOLESCENT; ADULT; CHILD; CHROMOSOME ABERRATION; GENETICS; METHODOLOGY; MYELOID LEUKEMIA; PREDICTION AND FORECASTING; PRESCHOOL CHILD; SENSITIVITY AND SPECIFICITY;

CUCURBITA; INSERTION SEQUENCES;

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; FUSION PROTEINS, BCR ABL; ONCOPROTEIN; PML RARALPHA PROTEIN; PML-RARALPHA PROTEIN; TUMOR PROTEIN;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; FEMALE; FUSION PROTEINS, BCR-ABL; HUMAN; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, MYELOID; MALE; MIDDLE AGE; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 0035543193     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(01)00504-0     Document Type: Article

References (43)

1. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining
2. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukemia
3. The molecular genetics of Philadelphia chromosome +ve leukemia
4. The PML-RARA fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RARA
5. FISH detection of mixed chimerism in 33 patients submitted to bone marrow transplantation
6. Interferon-alpha produces sustained cytogenetic response in chronic myelogenous leukemia Philadelphia chromosome +ve patients
7. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?
8. Detection of chimeric BCR-ABL genes on bone marrow sample and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization
9. Polymerase chain reaction; the molecular microscope of residual disease
10. Usefulness of detection of minimal residual disease by hypermetaphase fluorescence in situ hybridization after allogeneic BMT for chronic myelogenous leukemia
11. Detection of residual leukemic cells in patients with acute promyelocytic leukemia by the fluorescence in situ hybridization methods; potential for predicting relapse
12. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals; Biologic significance and implication for the assessment of minimal residual disease
13. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukemia
14. Application of fluorescence in situ hybridization to detect residual leukemic cells with 9;22 and 15;17 translocations
15. Prolonged survival in chronic myelognous leukemia after cytogenetic response to Interferon-alpha therapy
16. Disappearance of Ph 1 +ve cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from identical twins
17. Leukocytes interferon-induced myeloid cytoreduction in chronic myelogenous leukemia
18. Interferon-alpha therapy for chronic myelogenous leukemia
19. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia
20. Acute promyelocytic leukemia; all trans retinoic acid (ATRA) along with chemotherapy is superior to ATRA alone
21. Acute promyelocytic leukemia; MD Anderson Hospital experience
22. Acute promyelocytic leukemia; treatment results during a decade at Memorial Hospital
23. Use of arsenic trioxide (as 203) in the treatment of acute promyelocytic leukemia (APL); II clinical efficacy and pharmacokinetics in relapsed patients
24. Hematologic remission and cytogenetic improvement induced by recombinant human interferon-alpha in chronic myelogenous leukemia
25. Combined cytogenetic, FISH and molecular analysis in acute promyelocytic leukemia at diagnosis and in complete remission
26. The application of fluorescence in situ hybridization to detect M bcr/abl fusion in variant Ph chromosomes in CML and ALL
27. A detection of the M bcr/abl translocation in chronic myeloid leukemia by fluorescence in situ hybridization; comparison with conventional cytogenetic and implementations for minimal residual disease detection
28. Hyper Metaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with myelogenous leukemia during treatment
29. Cell lineage specific involvement in acute promyelocytic leukemia (APL) using a combination of May-Grunwald-Giemsa staining and fluorescence in situ hybridization techniques for the detection of the translocation t(15;17)(q22;q12)
30. Value of fluorescence in situ hybridization for detecting the bcr/abl gene fusion in interphase cells of routine bone marrow specimens
31. High incidence of a second BCR-ABL fusion in chronic myeloid leukemia revealed by interphase cytogenetic analysis on blood and bone marrow smears
32. Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia
33. Detection of the Philadelphia chromosome in paraffin-embedded tissue by fluorescence in situ hybridization
34. Detection of bcr-abl fusion in chronic myeloid leukemia by in situ hybridization
35. Clinical detection of bcr-abl fusion by in situ hybridization is chronic myelogenous leukemia
36. Trilateral retinoblastoma with an RB1 deletion inherited from a carrier mother; a case report
37. Cytogenetic analysis in non informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-α (IFN-α) therapy
38. Polymerase chain reaction detection of the bcr-abl fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia; results and implications in 346 patients
39. Prognostic significance of Philadelphia chromosome +ve cells detected by Polymerase chain reaction after allogenic bone marrow transplantation in chronic myelogenous leukemia
40. Frequent detection of bcr-abl specific mRNA in patients with chronic myeloid leukemia (CML) following allogeneic and syngeneic bone marrow transplantation (BMT)
41. Detection of minimal residual disease after sex-mismatch bone marrow transplantation in chronic myelogenous leukemia by fluorescence in situ hybridization
42. Translocation of bcr to chromosome 9; A new cytogenetic variant detected by FISH in two Ph negative BCR-positive patients with chronic myeloid leukemia
43. Duplication of chromosome 9 carrying a BCR/ABL chimeric gene in Philadelphia negative chronic myeloid leukemia